Zolbetuximab plus CAPOX versus CAPOX in first-line treatment of claudin18.2(+)/HER2(-) advanced/metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW phase 3 study-MedSci.cn

Zolbetuximab plus CAPOX versus CAPOX in first-line treatment of claudin18.2(+)/HER2(-) advanced/metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW phase 3 study

Shah, MA; Ajani, JA; Al-Batran, SE; Bang, YJ; Catenacci, DVT; Enzinger, PC; Ilson, DH; Kim, SS; Lordick, F; Shitara, K; Van Cutsem, E; Arozullah, A; Raizer, JJ; Park, JW; Xu, RH

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (4):

科室
- - 订阅+
  - 更多科室
工具
服务